Role of 5α-reductase inhibitors in benign prostatic diseases

@article{Azzouni2012RoleO5,
  title={Role of 5$\alpha$-reductase inhibitors in benign prostatic diseases},
  author={F. Azzouni and J. Mohler},
  journal={Prostate Cancer and Prostatic Diseases},
  year={2012},
  volume={15},
  pages={222-230}
}
Testosterone is the most abundant androgen in serum. Intracellularly, testosterone is converted to dihydrotestosterone, the preferred ligand for androgen receptor transactivation, by the enzyme 5α-reductase. Three 5α-reductase isozymes have been discovered and they are expressed ubiquitously in human tissues. Testosterone and dihydrotestosterone have different but complimentary functions. Dihydrotestosterone has 2–5 times higher binding affinity for the androgen receptor than testosterone, and… Expand
Apoptotic Pathways Linked to Endocrine System as Potential Therapeutic Targets for Benign Prostatic Hyperplasia
A review of the effects and molecular mechanisms of dimethylcurcumin (ASC‐J9) on androgen receptor‐related diseases
Updated survey of the steroid-converting enzymes in human adipose tissues
...
1
2
...

References

SHOWING 1-10 OF 93 REFERENCES
5α-Reductase Isozymes in the Prostate.
Androgens and male physiology the syndrome of 5alpha-reductase-2 deficiency.
The influence of finasteride on the development of prostate cancer.
Differences in steroid 5α-reductase iso-enzymes expression between normal and pathological human prostate tissue
...
1
2
3
4
5
...